Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Faivre SJ, Olszanski AJ, Weigang-Köhler K, Riess H, Cohen RB, Wang X, Myrand SP, Wickremsinhe ER, Horn CL, Ouyang H, Callies S, Benhadji KA, Raymond E. Faivre SJ, et al. Among authors: raymond e. Invest New Drugs. 2015 Dec;33(6):1206-16. doi: 10.1007/s10637-015-0286-7. Epub 2015 Sep 16. Invest New Drugs. 2015. PMID: 26377590 Clinical Trial.
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Hilgers W, Faivre S, Chieze S, Alexandre J, Lokiec F, Goldwasser F, Raymond E, Kahatt C, Taamma A, Weems G, MacDonald JR, Misset JL, Cvitkovic E. Hilgers W, et al. Among authors: raymond e. Invest New Drugs. 2006 Jul;24(4):311-9. doi: 10.1007/s10637-005-5055-6. Invest New Drugs. 2006. PMID: 16683074 Clinical Trial.
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Alexandre J, Kahatt C, Bertheault-Cvitkovic F, Faivre S, Shibata S, Hilgers W, Goldwasser F, Lokiec F, Raymond E, Weems G, Shah A, MacDonald JR, Cvitkovic E. Alexandre J, et al. Among authors: raymond e. Invest New Drugs. 2007 Oct;25(5):453-62. doi: 10.1007/s10637-007-9071-6. Epub 2007 Jul 13. Invest New Drugs. 2007. PMID: 17628744 Clinical Trial.
Induction chemotherapy challenges for head and neck cancer.
Faivre S, Albert S, Raymond E. Faivre S, et al. Among authors: raymond e. Lancet Oncol. 2013 Mar;14(3):188-9. doi: 10.1016/S1470-2045(13)70023-8. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414586 No abstract available.
[Irinotecan and liver dysfunctions].
Sablin MP, Le Tourneau C, Faivre S, Raymond E. Sablin MP, et al. Among authors: raymond e. Therapie. 2007 Mar-Apr;62(2):111-5. doi: 10.2515/therapie:2007024. Epub 2007 Jun 21. Therapie. 2007. PMID: 17582311 French.
596 results